Bio-Techne CEO gets 57,590 and 93,582 RSUs
BIO-TECHNE Corp (TECH) reported that its Chief Executive Officer, Kim Kelderman, received equity awards of 57,590 and 93,582 restricted stock units on August 17, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BIO-TECHNE Corp (TECH) reported that its Chief Executive Officer, Kim Kelderman, received equity awards of 57,590 and 93,582 restricted stock units on August 17, 2026. Each unit represents one share of BIO-TECHNE common stock.
The 57,590 RSUs vest in three installments of 19,197, 19,197, and 19,196 units on August 17, 2027, 2028, and 2029. The 93,582 RSUs vest on August 17, 2029. Separately, Kelderman directly holds 82,762 BIO-TECHNE common shares and multiple stock option grants, including options over 115,724 shares at an exercise price of $66.97 expiring August 5, 2027.
Insider Trade Summary
Grant/Award: 151,172 shares
Grant/Award
17 txns
Insider
Kelderman Kim
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units F7, F12 | 57,590 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units F7, F13 | 93,582 | $0.00 | $0.00 |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F4 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F5 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F6 | -- | -- | -- |
| holding | Performance Restricted Stock Units F7, F8 | -- | -- | -- |
| holding | Performance Restricted Stock Units F7, F9 | -- | -- | -- |
| holding | Restricted Stock Units F7, F10 | -- | -- | -- |
| holding | Restricted Stock Units F7, F11 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 183,285 contracts for 32,113 underlying shares (Direct);
Stock Option (Right to Buy) — 141,668 contracts (Direct);
Stock Options (Right to Buy) — 311,088 contracts (Direct);
Performance Restricted Stock Units — 121,969 contracts (Direct);
Common Stock — 82,762 shares (Direct)
Footnotes (13)
- F1. Fully exercisable.
- F2. Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
- F3. Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
- F4. Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
- F5. Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
- F6. Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
- F7. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F8. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F9. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F10. 8,544 restricted stock units vest on 8/15/2027.
- F11. 11,785 restricted stock units vest on 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
- F12. 19,197 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 19,196 restricted stock units vest on 8/17/2029.
- F13. 93,582 restricted stock units vest on 8/17/2029.
Key Figures
Time-based RSU grant: 57,590 shares
Time-based RSU grant: 93,582 shares
Direct common stock holding: 82,762 shares
+5 more
8 metrics
Time-based RSU grant
57,590 shares
Restricted stock units granted 2026-08-17, vesting 2027-2029 in three installments
Time-based RSU grant
93,582 shares
Restricted stock units granted 2026-08-17, vesting on 2029-08-17
Direct common stock holding
82,762 shares
Common stock directly owned by CEO Kim Kelderman after reported transactions
Stock option exercise price
$66.97
Option over 115,724 underlying shares expiring 2027-08-05
Underlying shares for $66.97 options
115,724 shares
Stock option (right to buy) BIO-TECHNE common stock at $66.97
Highest reported option exercise price
$120.46
Stock option over 25,944 underlying shares expiring 2028-08-06
Performance RSUs block
51,261 shares
Performance restricted stock units that may vest based on goals by 2027
Performance RSUs block
70,708 shares
Performance restricted stock units that may vest based on goals by 2028
Key Terms
Restricted Stock Units, Performance Restricted Stock Units, Stock Options (Right to Buy)
3 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Restricted Stock Units financial
"Vests in full or in part on 8/15/2027 if certain performance goals"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with various exercise prices and expirations"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did BIO-TECHNE (TECH) grant to CEO Kim Kelderman on August 17, 2026?
BIO-TECHNE (TECH) granted CEO Kim Kelderman 57,590 and 93,582 restricted stock units on August 17, 2026. Each restricted stock unit represents a contingent right to receive one share of BIO-TECHNE common stock, subject to the stated vesting schedules.
How do the newly granted TECH restricted stock units to the CEO vest?
The 57,590 restricted stock units vest in three tranches on August 17, 2027, 2028, and 2029 (19,197; 19,197; 19,196 units). The 93,582 restricted stock units vest in full on August 17, 2029, subject to continued service and award terms.
What stock options in BIO-TECHNE (TECH) does the CEO have outstanding?
Outstanding stock options include grants over 115,724 shares at $66.97 expiring August 5, 2027, and several other option blocks with exercise prices between $52.83 and $120.46. These options give rights to purchase BIO-TECHNE common stock before their respective expiration dates.
What performance-based equity holdings in BIO-TECHNE (TECH) does the CEO report?
The CEO reports performance restricted stock units covering 51,261 and 70,708 underlying shares of BIO-TECHNE common stock. These performance RSUs vest in full or in part on specified future dates if certain performance goals are achieved and subsequently certified.
AI-generated analysis. How Rhea-AI works. Not financial advice.
